These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19242927)

  • 1. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia.
    Kim YN; Lee DS; Jeong DH; Sung MS; Kim KT
    Prenat Diagn; 2009 May; 29(5):464-70. PubMed ID: 19242927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
    Buhimschi CS; Norwitz ER; Funai E; Richman S; Guller S; Lockwood CJ; Buhimschi IA
    Am J Obstet Gynecol; 2005 Mar; 192(3):734-41. PubMed ID: 15746665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia.
    Masuyama H; Segawa T; Sumida Y; Masumoto A; Inoue S; Akahori Y; Hiramatsu Y
    BJOG; 2010 Feb; 117(3):314-20. PubMed ID: 20015306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia.
    Park CW; Park JS; Shim SS; Jun JK; Yoon BH; Romero R
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):984-9. PubMed ID: 16157098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.
    Chaiworapongsa T; Romero R; Kim YM; Kim GJ; Kim MR; Espinoza J; Bujold E; Gonçalves L; Gomez R; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jan; 17(1):3-18. PubMed ID: 15804781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
    Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive value of serum soluble fms-like tyrosine kinase 1 concentration in preeclampsia at second trimester].
    Ye YH; Liu L; Zhan Y; Peng W
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):433-5. PubMed ID: 17083803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and significance of soluble fms-like tyrosine kinase 1 in preeclampsia placenta].
    Ye YH; Liu L; Zhan Y; Peng W
    Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):521-4. PubMed ID: 17083834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early onset preeclampsia and second trimester serum markers.
    Lambert-Messerlian GM; Palomaki GE; Neveux LM; Chien E; Friedman A; Rosene-Montella K; Hayes M; Canick JA
    Prenat Diagn; 2009 Dec; 29(12):1109-17. PubMed ID: 19842088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alteration and potential role of soluble fms-like tyrosine kinase receptor 1 in preeclampsia].
    Li Y; Li DH; Yao YQ; Min BH; Zhang CL; Hou XH; Huang L; Zhao HX
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):581-4. PubMed ID: 16202309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.
    Powers RW; Roberts JM; Cooper KM; Gallaher MJ; Frank MP; Harger GF; Ness RB
    Am J Obstet Gynecol; 2005 Jul; 193(1):185-91. PubMed ID: 16021077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preeclampsia and fetal growth.
    Odegård RA; Vatten LJ; Nilsen ST; Salvesen KA; Austgulen R
    Obstet Gynecol; 2000 Dec; 96(6):950-5. PubMed ID: 11084184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-receptor levels in preeclampsia--results of a longitudinal study in high-risk women.
    Schipper EJ; Bolte AC; Schalkwijk CG; Van Geijn HP; Dekker GA
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):283-7. PubMed ID: 16390786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.
    Verlohren S; Galindo A; Schlembach D; Zeisler H; Herraiz I; Moertl MG; Pape J; Dudenhausen JW; Denk B; Stepan H
    Am J Obstet Gynecol; 2010 Feb; 202(2):161.e1-161.e11. PubMed ID: 19850276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop.
    McKeeman GC; Ardill JE; Caldwell CM; Hunter AJ; McClure N
    Am J Obstet Gynecol; 2004 Oct; 191(4):1240-6. PubMed ID: 15507947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.
    Chaiworapongsa T; Romero R; Espinoza J; Bujold E; Mee Kim Y; Gonçalves LF; Gomez R; Edwin S
    Am J Obstet Gynecol; 2004 Jun; 190(6):1541-7; discussion 1547-50. PubMed ID: 15284729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
    Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
    Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia.
    Shokry M; Bedaiwy MA; Fathalla MM; Alsemary A; Elwakil S; Murphy A
    Acta Obstet Gynecol Scand; 2010; 89(1):143-6. PubMed ID: 20021269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.